DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Eli Lilly's - 8 Eli Lilly - 6 CNBC's Jim Cramer - 2 it's - 2 Cramer - 2 Eisai - 2 Jim Cramer - 2 Jim - 2
Top related locs:
U.S Biogen Indianapolis , Indiana Black Figma North Concord , North Carolina Indianapolis
Top related orgs:
FDA - 5 Food and Drug Administration - 2 CNBC - 2 Discovery Foundation - 1 Nvidia - 1 Apple - 1 Apple's - 1 Conference - 1

Search resuls for: "Eli Lilly's Alzheimer's"


15 mentions found


☆ Dr. Fillit on Eli Lilly's Alzheimer's drug: Really having breakthroughs & success for the first time
  + stars: | 2024-06-11 | by ( ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailDr. Fillit on Eli Lilly's Alzheimer's drug: Really having breakthroughs & success for the first timeDr. Howard Fillit, Alzheimer’s Drug Discovery Foundation co-founder and chief science officer, joins 'Squawk Box' to discuss news of FDA panel's approval of Eli Lilly's Alzheimer's drug Donanemab, the future of Alzheimer's treatments, and more.
Persons: Fillit, Eli Lilly's Alzheimer's, Howard Fillit, Eli Lilly's Organizations: Discovery Foundation, FDA
☆ Jim Cramer says Eli Lilly isn't a 'one trick pony' after FDA advisers endorse its Alzheimer's drug
  + stars: | 2024-06-11 | by ( Julie Coleman | ) www.cnbc.com   time to read: +2 min
CNBC's Jim Cramer on Tuesday explained why he continues to be bullish about pharmaceutical giant Eli Lilly . Continually confident about Eli Lilly because of the enormous success of its weight loss and diabetes drugs, he said the company's new Alzheimer's treatment has the potential to further boost business. On Monday, a panel of advisors to the Food and Drug Administration unanimously recommended Eli Lilly's Alzheimer's drug, currently known as donanemab. "I think this advisory committee decision on their Alzheimer's drug does precisely that." Eli Lilly did not immediately respond to request for comment.
Persons: CNBC's Jim Cramer, Eli Lilly, Eli Lilly's, it's, Cramer, they've Organizations: Food and Drug Administration, FDA Locations: U.S, Biogen
☆ FDA advisors recommend Eli Lilly's Alzheimer's drug donanemab, paving way for approval
  + stars: | 2024-06-10 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +4 min
Eli Lilly headquarters in Indianapolis, Indiana, US, on Wednesday, May 3, 2023. A panel of independent advisors to the Food and Drug Administration on Monday recommended Eli Lilly 's Alzheimer's drug donanemab, paving the way for the treatment to receive full approval in the U.S. later this year. If cleared for use, Eli Lilly's donanemab would become the second Alzheimer's drug of its kind to enter the U.S. market after another treatment called Leqembi from Biogen and its Japanese partner Eisai. In a second vote, advisors unanimously said the benefits of Eli Lilly's donanemab outweigh its risks. It was another blow to Eli Lilly, which initially expected donanameb to win approval at the end of last year.
Persons: Eli Lilly, Eli Lilly's donanemab, Eisai, Eli Lilly's, Sarah Dolan, Dolan, Mark Mintun, donanameb, Leerink, David Risinger, Risinger Organizations: Food and Drug Administration, FDA Locations: Indianapolis , Indiana, U.S, Biogen, Black
☆ FDA advisers say Eli Lilly's Alzheimer's treatment is effective
  + stars: | 2024-06-10 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailFDA advisers say Eli Lilly's Alzheimer's treatment is effectiveCNBC's Angelica Peebles joins 'Closing Bell' to discuss the FDA's advisers vote on Eli Lilly's Alzheimer's drug.
Persons: Eli Lilly's, Angelica Peebles
☆ Jim Cramer's week ahead: Fed meeting and CPI report
  + stars: | 2024-06-07 | by ( Julie Coleman | ) www.cnbc.com   time to read: +2 min
CNBC's Jim Cramer on Friday guided investors through next week's most market-moving events, highlighting the Federal Reserve's meeting and the latest consumer price index report. Nvidia will implement its 10-for-1 stock split, and Cramer said shares might drop on Monday as buyers take profits. Oracle reports on Tuesday, and Cramer said he's not sure how this enterprise software company will fare. Casey's General Stores will also report that day, and Cramer said business is strong and the stock has been "a total winner." In that vein, the Fed will likely leave rates higher for longer at its Wednesday meeting, Cramer said.
Persons: CNBC's Jim Cramer, Jay Powell, Eli Lilly, Cramer, Eli Lilly's, he's, hasn't, nonfarm, He'll Organizations: Nvidia, Apple, Apple's, Conference, Vision Pro, FDA, Oracle, Casey's, Broadcom, Signet, Adobe Locations: Figma
☆ Eli Lilly's rally on blowout Mounjaro sales signals a new leg higher for the stock
  + stars: | 2023-11-02 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com   time to read: +8 min
LLY YTD mountain Eli Lilly's year-to-date stock performance. Investors are understandably cheering the results, sending Eli Lilly shares higher by more than 4%. "Eli Lilly today is beginning its next leg of going up," Jim Cramer said during Thursday's Morning Meeting . The most important line item was Mounjaro sales, which cleared Wall Street's high bar. Excluding that divestiture and the $387 million in Covid antibody sales in the year-ago quarter, Eli Lilly's sales grew 24% on an annual basis — a highly respectable figure.
Persons: Eli Lilly, LLY, Mounjaro, it's, Eli Lilly's, Jim Cramer, Jim, It's, Novo's, Lilly, We're, Dave Ricks, Ricks, Trulicity, Anat Ashkenazi, Lilly —, Ashkenazi, Jim Cramer's, David Ricks, Eli Lilly Scott Mlyn Organizations: Drug Administration, FDA, Novo Nordisk, CNBC, Management, Dice Therapeutics, Therapeutics Locations: North, Concord , North Carolina, U.S, Indianapolis
☆ 3 health-care stocks are in the headlines. How the news impacts our investments
  + stars: | 2023-07-13 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com   time to read: +8 min
In April, alongside its first-quarter results, J & J raised its full-year sales guidance by about $1 billion and its earnings-per-share outlook by 15 cents. Clearing this overhang would help reduce the discount at which J & J shares to pharmaceutical peers, the firm said. The Club's take: JPMorgan's thinking on J & J aligns quite closely with our own. The dark cloud of talc lawsuits continues to keep a lid on J & J's stock price. Joaquin Duato, chief executive officer of Johnson & Johnson, at the company's headquarters in New Brunswick, New Jersey, U.S., on Thursday, April 21, 2022.
Persons: Johnson, Eli Lilly, J, Wells, Wells Fargo, Eli Lilly's, —, Eisai, Biogen, Bloomberg, we've, Jim Cramer's, Jim Cramer, Jim, Joaquin Duato, Amir Hamia Organizations: Johnson, JPMorgan, pharma, U.S ., Humana, UnitedHealth, Bloomberg, U.S, Mayo Clinic, Club, GE Healthcare, CNBC, Getty, & $ Locations: U.S, California, Wells Fargo, Rochester , Minnesota, New Brunswick , New Jersey
☆ Vast utility for weight loss drugs will more than pay for themselves, says Eli Lilly CEO David Ricks
  + stars: | 2023-06-13 | by ( ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailVast utility for weight loss drugs will more than pay for themselves, says Eli Lilly CEO David RicksEli Lilly CEO David Ricks joins CNBC's Bertha Coombs and 'The Exchange' live from the World Medical Innovation Forum to discuss Eli Lilly's alzheimer's treatment, concerns over coverage reimbursement schemes, and upcoming drug price negotiations.
Persons: Eli Lilly, David Ricks Eli Lilly, David Ricks, Bertha Coombs, Eli Lilly's
☆ Cramer's First Take: Eli Lilly's Alzheimer's drug is 'the holy grail'
  + stars: | 2023-05-03 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailCramer's First Take: Eli Lilly's Alzheimer's drug is 'the holy grail'CNBC's Jim Cramer shares his thoughts on Eli Lilly's Alzheimer's drug and the banking turmoil.
☆ Alzheimer’s patients may wait years to get treated with new drugs, putting them at risk of more severe disease
  + stars: | 2023-04-30 | by ( Spencer Kimball | ) www.cnbc.com   time to read: +17 min
But time spent waiting robs early patients of their memory and ability to live independently. This condition is often, though not always, a sign of early Alzheimer's disease. PET scans cumbersomeTwo types of tests can diagnosis Alzheimer's disease: PET scans and spinal taps. Early Alzheimer's disease can also be diagnosed with a spinal tap, in which fluid around the spinal cord is extracted with a catheter and tested. He believes big players like CVS will provide infusions for Alzheimer's disease on a major scale if they see there's a large and stable market.
☆ Eli Lilly, Apple and Salesforce each made news on Thursday — our Club takes
  + stars: | 2023-03-09 | by ( Kevin Stankiewicz | ) www.cnbc.com   time to read: +7 min
A trio of Club stocks — Eli Lilly (LLY), Apple (AAPL) and Salesforce (CRM) — are in the news Thursday. The news: Eli Lilly is ending clinical development for one of its older Alzheimer's drugs — known as solanezumab — following another failed trial. Eli Lilly shares have struggled so far this year, falling more than 13%. In a note to clients, the firm said Eli Lilly "remains one of our favorite names" in the industry. The Eli Lilly logo is shown on one of the company's offices in San Diego, California, September 17, 2020.
☆ Jim Cramer explains why he's bullish on Eli Lilly despite its Alzheimer's drug's regulatory obstacle
  + stars: | 2023-01-23 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailJim Cramer explains why he's bullish on Eli Lilly despite its Alzheimer's drug's regulatory obstacleCramer explained why the regulatory obstacle facing Eli Lilly's Alzheimer's drug doesn't change his opinion of the stock.
☆ Eli Lilly's Alzheimer's drug hits a regulatory hurdle. But our belief in the stock isn't shaken
  + stars: | 2023-01-20 | by ( Kevin Stankiewicz | ) www.cnbc.com   time to read: +8 min
Eli Lilly 's (LLY) attempt to receive accelerated regulatory approval for its Alzheimer's drug donanemab has been rejected. Eli Lilly said it will keep working with the FDA to "evaluate the fastest pathway" for donanemab to reach patients. Indeed, analysts at Barclays wrote in a note to clients Thursday that "we now see [accelerated approval] off the table." LLY 1Y mountain Eli Lilly (LLY) 1-year performance "It's definitely not a thesis-breaker," Bank of America analyst Geoff Meacham told CNBC on Friday. David Ricks, CEO, Eli Lilly Scott Mlyn | CNBC
☆ What increasing confidence in Biogen's latest Alzheimer's drug means for Eli Lilly
  + stars: | 2022-11-30 | by ( ) www.cnbc.com   time to read: +6 min
Donanemab is the name of Eli Lilly's Alzheimer's drug in its own late-stage trials. JPMorgan has a neutral (hold) rating on Biogen shares and an overweight (buy) rating on Eli Lilly shares. What it means for Eli Lilly Eli Lilly has a phase three trial underway for its donanemab Alzheimer's drug that is similar to lecanemab, which is why the Biogen-Eisai data has been interpreted as favorable for the Club holding. Clumps of the protein, known as amyloid plaques, are one of the key markers of Alzheimer's disease. Previous drugs developed around the a-beta hypothesis — including those from Eli Lilly — have failed to meaningfully delay the disease's progression.
☆ UBS upgrades Eli Lilly to buy, says it's developing possibly ‘the biggest drug ever’
  + stars: | 2022-09-22 | by ( Carmen Reinicke | ) www.cnbc.com   time to read: +2 min
UBS is moving off the sidelines and saying now is the time to snap up Eli Lilly citing a key weight loss drug. The rating change comes after mounjaro, or tirzepatide, a key weight loss drug, showed promise in a random study called Surmount-1 and was approved for use in patients with type 2 diabetes. Weight loss drug could be biggest ever The weight loss drug could be the "biggest drug ever" with estimated peak annual sales of $25 billion, according to the firm's estimate. Several drug companies have weight loss drugs in development , making it a possible big driver of the stocks in coming years. In the near-term, there is downside risk if the company's weight loss drug is not able to file for use in obesity, the note said.
0 next >>
Total: 15